Lung Cancer Liquid Biopsy Market Set for 12.7% CAGR Growth Through 2032: Persistence Market Research

The global lung cancer liquid biopsy market is rapidly evolving, fueled by the urgent need for non-invasive, accurate, and early cancer diagnostic tools. Liquid biopsies offer a transformative approach to diagnosing and monitoring lung cancer by detecting biomarkers in body fluids like blood, thereby reducing the need for invasive tissue biopsies.

In 2025, the market is valued at US$ 824.7 million and is projected to reach US$ 1,900.5 million by 2032, growing at a CAGR of 12.7% during the forecast period. This growth is underpinned by increasing incidences of lung cancer globally, rising awareness about early cancer detection, and ongoing innovation in genomic technologies such as next-generation sequencing (NGS) and digital PCR.

The NGS-based multi-gene parallel analysis segment leads the market due to its capability to detect a wide range of genetic alterations with high precision. Additionally, North America dominates the global landscape owing to its advanced healthcare infrastructure, high awareness levels, robust reimbursement policies, and strong clinical research initiatives.

✅Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35195

Key Highlights from the Report

➤ The global lung cancer liquid biopsy market is projected to reach $1.9 billion by 2032.
➤ North America dominates the market due to advanced healthcare infrastructure and high disease prevalence.
➤ The NGS segment accounts for the highest revenue share owing to its high diagnostic accuracy.
➤ Rising demand for non-invasive and early lung cancer diagnostics is fueling market expansion.
➤ Strategic partnerships and FDA approvals are shaping competitive dynamics.
➤ Innovations in digital PCR and microRNA biomarker research are creating new growth avenues.

How is the Market Segmented by Product, Application, and End-User?

By Product Type:

The market is primarily segmented into Kits & Reagents, Instruments, and Services. Among these, kits and reagents dominate with over 71.2% market share in 2024, driven by their recurring use in sample processing and analysis. These components are essential for extracting and amplifying tumor-derived nucleic acids from liquid biopsies.

By Application:

Key applications include early cancer screening, therapy selection, treatment monitoring, and recurrence detection. Early detection and therapy selection are currently the leading segments. Their relevance continues to grow as healthcare systems prioritize early diagnosis and personalized treatment regimens, especially for non-small cell lung cancer (NSCLC).

By End-User:

Major end-users include hospitals, diagnostic laboratories, academic and research institutes, and biopharma companies. Hospitals and diagnostic labs are the leading end-users due to their direct involvement in cancer diagnosis and patient management. Academic institutions are also emerging as key stakeholders, especially in biomarker discovery and clinical validation.

Which Regions Are Leading the Market and Why?

North America:

North America, led by the U.S., held a 47.8% share in 2024. The high burden of lung cancer (over 226,000 new cases annually) and the widespread availability of advanced diagnostic technologies are major contributors. Robust funding, such as Roche's $254 million investment in Freenome, enhances diagnostic platforms and speeds up commercialization. The FDA's rapid approval process for liquid biopsy CDx tools further propels regional growth.

Asia Pacific:

Asia Pacific is emerging as the fastest-growing region with a projected CAGR of 15.6% through 2032. Rising cancer prevalence, improving healthcare access, and the increasing affordability of diagnostic technologies are driving demand. China and Japan are early adopters of liquid biopsy, while India's affordable diagnostic initiatives-like Johnson & Johnson's "India Detects to Defeat" campaign-are enhancing awareness and early screening.

Europe also holds a significant 28.6% market share, with strong government support, collaborative research environments, and reimbursement policies. The Royal Marsden-Guardant Health partnership in the UK exemplifies regional innovation and integration into public health systems.

What Factors Are Driving Growth in the Lung Cancer Liquid Biopsy Market?

Market Drivers:

The growing preference for non-invasive diagnostic tools is a primary driver. Traditional tissue biopsies are invasive, risky, and not always feasible-especially for advanced or metastatic patients. Liquid biopsies, using blood samples to detect circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs), offer a painless and safer alternative.

Advancements in NGS and digital PCR technologies allow precise and early detection of genetic mutations. Simultaneously, biomarker discoveries such as microRNAs and exosomes are expanding the diagnostic capabilities of liquid biopsy platforms.

Government funding, academic partnerships, and increased clinical trial activity-like BioMark Diagnostics' pivotal lung cancer study and Freenome's PROACT LUNG trial-are accelerating the market.

Market Restraints:

Despite its promise, liquid biopsy faces technical and economic hurdles. The primary concern is the limited sensitivity of biomarkers, especially for early-stage cancers. Tumor-derived DNA or CTCs often occur in trace amounts during early progression, making detection inconsistent.

Lack of standardization in liquid biopsy testing protocols and high costs associated with NGS or targeted panels limit accessibility, particularly in low-income regions. Additionally, insurance reimbursement is not uniform across countries, creating disparities in adoption rates.

These challenges necessitate improved assay sensitivity, global testing guidelines, and cost-effective solutions for broader integration into clinical settings.

✅Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35195

Market Opportunities:

Liquid biopsy is increasingly being used as a companion diagnostic (CDx) tool to guide targeted lung cancer therapies, especially for detecting EGFR, ALK, and MET mutations. The FDA's approval of FoundationOne®Liquid CDx for TEPMETKO® is a landmark development, highlighting the potential of liquid biopsy in personalized oncology.

Falling NGS costs and the rising adoption of multi-gene panel assays make liquid biopsy more scalable. Emerging markets like India and Brazil, supported by public health initiatives and local biotech innovation, represent untapped opportunities for growth.

Biopharma collaborations are also opening new channels for market expansion. Companies like Guardant Health and Boehringer Ingelheim are co-developing targeted therapies validated by liquid biopsy platforms, shaping the future of precision medicine.

Frequently Asked Questions about the Lung Cancer Liquid Biopsy Market

➤ How Big is the Lung Cancer Liquid Biopsy Market in 2024?
➤ Who are the Key Players in the Global Lung Cancer Liquid Biopsy Market?
➤ What is the Projected Growth Rate of the Lung Cancer Liquid Biopsy Market?
➤ What is the Market Forecast for the Lung Cancer Liquid Biopsy Market through 2032?
➤ Which Region is estimated to dominate the Lung Cancer Liquid Biopsy Market during the Forecast Period?

Company Insights: Leading Players in the Lung Cancer Liquid Biopsy Market

✦ Guardant Health, Inc.
✦ Foundation Medicine, Inc.
✦ Illumina, Inc.
✦ F. Hoffmann-La Roche Ltd
✦ BioMark Diagnostics Inc.
✦ Freenome Holdings, Inc.
✦ QIAGEN
✦ Thermo Fisher Scientific Inc.

Recent Developments in the Lung Cancer Liquid Biopsy Market

■ Guardant Health and Boehringer Ingelheim partnered in December 2024 to co-commercialize Guardant360® CDx as a companion diagnostic for zongertinib in NSCLC.
■ In January 2025, Viz.ai partnered with Guardant Health to integrate AI and genomics for faster and more accurate lung cancer diagnostics through the Viz.ai One platform.

Conclusion

The global lung cancer liquid biopsy market is on a robust growth trajectory, projected to grow from US$ 824.7 million in 2025 to US$ 1,900.5 million by 2032, at a CAGR of 12.7%. Rising lung cancer prevalence, demand for non-invasive diagnostic tools, and cutting-edge genomic technologies are shaping this expansion.

Key technologies like NGS and digital PCR, combined with innovative biomarkers, are redefining lung cancer screening and treatment planning. Although challenges such as cost and sensitivity persist, strategic partnerships, regulatory approvals, and increasing use in companion diagnostics signal a promising future.

Emerging markets and a push toward personalized medicine will further widen the market scope, making lung cancer liquid biopsy a pivotal component in the next generation of oncology care.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.